Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706521 · ClinicalTrials.gov registry record · Phase 2
MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis
A Phase 2 study, sponsored by Biosplice Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT03706521 is a Phase 2 study that was terminated before completion, run by Biosplice Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT03706521, a Phase 2 study, was terminated before completion, sponsored by Biosplice Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of lorecivivint (LOR) injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects. Efficacy was primarily evaluated via magnetic resonance imaging (MRI).
Interventions
- DRUG lorecivivint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03706521
The ClinicalTrials.gov registry entry for NCT03706521 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lorecivivint is the first listed.
NCT03706521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03706521 about?
NCT03706521 is a clinical study titled "MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis". The purpose of this study was to evaluate the safety and efficacy of lorecivivint (LOR) injected in the target knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects. Efficacy was primarily evaluated via magnetic resonance imaging (MRI).
What is the current status of trial NCT03706521?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-03-11. Estimated completion is 2020-12-21.
What interventions are being tested in trial NCT03706521?
The interventions under investigation include: lorecivivint (DRUG).
Who is sponsoring clinical trial NCT03706521?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.